INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024

BMH Summary 

INOVIO’s Q1 2024 earnings date announcement:

  • Q1 2024 Financial Results: INOVIO will release its first quarter 2024 financial results on May 13, 2024, after market close.
  • Conference Call and Webcast: A live conference call and webcast to discuss the financial results and provide a business update will be held at 4:30 p.m. ET on the same day.
  • Webcast Access: The webcast will be available online and will include a live Q&A session with analysts.
  • Webcast Replay: An archived version of the webcast will be available for replay for 90 days post-event.
  • Company Focus: INOVIO is dedicated to developing DNA medicines for treating and protecting against HPV-associated diseases, cancer, and infectious diseases.
  • Technology: INOVIO’s technology is designed to optimize the design and delivery of DNA medicines that enable the body to produce its own therapeutic agents.
  • Contact Information: Media and investor contact details have been provided for further inquiries.
Inovio

PLYMOUTH MEETING, Pa., April 29, 2024 /PRNewswire/ — INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that first quarter 2024 financial results will be released after the market close on May 13, 2024. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

The live webcast will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts. The webcast will be archived and available for replay for 90 days following the event.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO’s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

SOURCE INOVIO Pharmaceuticals, Inc.

Original press release can be found here.

Clinical
Image Source: Pexels.com